Patents by Inventor Knut Eis
Knut Eis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10966986Abstract: The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).Type: GrantFiled: February 3, 2017Date of Patent: April 6, 2021Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE INC.Inventors: Timothy A. Lewis, Alex Burgin, Monica Schenone, Xiaoyun Wu, Heidi Greulich, Matthew Meyerson, Luc De Waal, Antje Margret Wengner, Knut Eis, Philip Lienau, Ulrike Sack, Martin Lange
-
Patent number: 10894784Abstract: The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: December 15, 2016Date of Patent: January 19, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Volker Schulze, Tobias Heinrich, Florian Prinz, Julien Lefranc, Jens Schröder, Anne Mengel, Wilhelm Bone, Joszef Bálint, Antje Margret Wengner, Knut Eis, Horst Irlbacher, Marcus Koppitz, Ulf Bömer, Benjamin Bader, Hans Briem, Philip Lienau, Clara Christ, Detlef Stöckigt, Roman Hillig
-
Publication number: 20200383991Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 21, 2020Publication date: December 10, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Publication number: 20200377472Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 18, 2020Publication date: December 3, 2020Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Stefan Nikolaus GRADL, Duy NGUYEN, Knut EIS, Judith GÜNTHER, Timo STELLFELD, Andreas JANZER, Sven CHRISTIAN, Thomas MÜLLER, Sherif El SHEIKH, Han Jie ZHOU, Changjia ZHAO, David B. SYKES, Steven James FERRARA, Kery LIU, Michael KRÖBER, Claudia MERZ, Michael NIEHUES, Martina SCHÄFER, Katja ZIMMERMANN, Carl Friedrich NISING
-
Patent number: 10815215Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 25, 2017Date of Patent: October 27, 2020Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Stefan Nikolaus Gradl, Duy Nguyen, Knut Eis, Judith Günther, Timo Stellfeld, Andreas Janzer, Sven Christian, Thomas Müller, Sherif El Sheikh, Han Jie Zhou, Changjia Zhao, David B. Sykes, Steven James Ferrara, Kery Liu, Michael Kröber, Claudia Merz, Michael Niehues, Martina Schäfer, Katja Zimmermann, Carl Friedrich Nising
-
Patent number: 10772893Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 8, 2018Date of Patent: September 15, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Publication number: 20200123129Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 25, 2017Publication date: April 23, 2020Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Stefan Nikolaus GRADL, Duy NGUYEN, Knut EIS, Judith GÜNTHER, Timo STELLFELD, Andreas JANZER, Sven CHRISTIAN, Thomas MÜLLER, Sherif El SHEIKH, Han Jie ZHOU, Changjia ZHAO, David B. SYKES, Steven James FERRARA, Kery LIU, Michael KRÖBER, Claudia MERZ, Michael NIEHUES, Martina SCHÄFER, Katja ZIMMERMANN, Carl Friedrich NISING
-
Patent number: 10604532Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.Type: GrantFiled: March 21, 2019Date of Patent: March 31, 2020Assignees: Bayer Intellectual Property GmbH, Bayer Pharma AktiengesellschaftInventors: Marion Hitchcock, Anne Mengel, Vera Pütter, Gerhard Siemeister, Antje Margret Wengner, Hans Briem, Knut Eis, Volker Schulze, Amaury Ernesto Fernandez-Montalvan, Stefan Prechtl, Simon Holton, Jörg Fanghänel, Philip Lienau, Cornelia Preusse, Mark Jean Gnoth
-
Publication number: 20200087322Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 17, 2017Publication date: March 19, 2020Inventors: Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Clara Christ, Kai Thede, Joachim Kuhnke, Manfred Moewes, Knut Eis, Amaury Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Philip Lienau, Ulrike Sack, Arne Scholz, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren
-
Publication number: 20200062741Abstract: The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention.Type: ApplicationFiled: February 1, 2018Publication date: February 27, 2020Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: TIMOTHY A. LEWIS, XIAOYUN WU, HEIDI GREULICH, MATTHEW MEYERSON, MANUEL ELLERMANN, PHILIP LIENAU, KNUT EIS, ANTJE MARGRET WENGNER, CHARLOTTE CHRISTINE KOPITZ, MARTIN LANGE
-
Publication number: 20190375747Abstract: The present invention provides triazolone compounds compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 25, 2017Publication date: December 12, 2019Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Stefan Nikolaus GRADL, Duy NGUYEN, Knut EIS, Judith GÜNTHER, Timo STELLFELD, Andreas JANZER, Sven CHRISTIAN, Thomas MUELLER, Sherif El SHEIKH, Han Jie ZHOU, Changjia ZHAO, David B. SYKES, Steven James FERRARA, Kery LIU, Simon Anthony HERBERT, Claudia MERZ, Michael NIEHUES, Carl Friedrich NISING, Martina SCHÄFER, Katja ZIMMERMANN, Jörg KNÄBLEIN, Kai THEDE, Thomas FAUPEL
-
Publication number: 20190365770Abstract: The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).Type: ApplicationFiled: February 3, 2017Publication date: December 5, 2019Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.Inventors: TIMOTHY A. LEWIS, ALEX BURGIN, MONICA SCHENONE, XIAOYUN WU, HEIDI GREULICH, MATTHEW MEYERSON, LUC DE WAAL, ANTJE MARGRET WENGNER, KNUT EIS, PHILLIP LIENAU, ULRIKE SACK, MARTIN LANGE
-
Patent number: 10428044Abstract: Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.Type: GrantFiled: June 17, 2015Date of Patent: October 1, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Keith Graham, Ulrich Klar, Hans Briem, Marion Hitchcock, Lars Bärfacker, Knut Eis, Volker Schulze, Gerhard Siemeister, Wilhelm Bone, Jens Schröder, Simon Holton, Philip Lienau, René Tempel, Helmut Sonnenschein, Jozsef Bálint, Heinz Graubaum
-
Publication number: 20190284206Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.Type: ApplicationFiled: March 21, 2019Publication date: September 19, 2019Applicants: Bayer Intellectual Property GmbH, Bayer Pharma AktiengesellschaftInventors: Marion HITCHCOCK, Anne MENGEL, Vera PÜTTER, Gerhard SIEMEISTER, Antje Margret WENGNER, Hans BRIEM, Knut EIS, Volker SCHULZE, Amaury Ernesto FERNANDEZ-MONTALVAN, Stefan PRECHTL, Simon HOLTON, Jörg FANGHÄNEL, Philip LIENAU, Cornelia PREUSSE, Mark Jean GNOTH
-
Patent number: 10266548Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.Type: GrantFiled: February 21, 2017Date of Patent: April 23, 2019Assignees: Bayer Intellectual Property GmbH, Bayer Pharma AktiengesellschaftInventors: Marion Hitchcock, Anne Mengel, Vera Pütter, Gerhard Siemeister, Antje Margret Wengner, Hans Briem, Knut Eis, Volker Schulze, Amaury Ernesto Fernandez-Montalvan, Stefan Prechtl, Simon Holton, Jörg Fanghänel, Philip Lienau, Cornelia Preusse, Mark Jean Gnoth
-
Patent number: 10214545Abstract: The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, E, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: January 6, 2015Date of Patent: February 26, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Volker Schulze, Knut Eis, Florian Puehler, Ludwig Zorn, Detlev Sülzle, Philip Lienau, Antje Margret Wengner, Kirstin Petersen, Ulf Bömer
-
Publication number: 20190047980Abstract: The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2016Publication date: February 14, 2019Inventors: Volker SCHULZE, Tobias HEINRICH, Florian PRINZ, Julien LEFRANC, Jens SCHRÖDER, Anne MENGEL, Wilhelm BONE, Joszef BÁLINT, Antje Margret WENGNER, Knut EIS, Horst IRLBACHER, Marcus KOPPITZ, Ulf BÖMER, Benjamin BADER, Hans BRIEM, Philip LIENAU, Clara CHRIST, Detlef STÖCKIGT, Roman HILLIG
-
Publication number: 20180256591Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 8, 2018Publication date: September 13, 2018Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 9993484Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 3, 2015Date of Patent: June 12, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien LeFranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Publication number: 20180148418Abstract: The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredient.Type: ApplicationFiled: May 2, 2016Publication date: May 31, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Knut EIS, Jens ACKERSTAFF, Sarah WAGNER, Philipp BUCHGRABER, Detlev SÜLZLE, Simon HOLTON, Eckhard BENDER, Volkhart LI, Ningshu LIU, Franziska SIEGEL, Philip LIENAU, Michaela BAIRLEIN, Franz VON NUSSBAUM, Simon Anthony HERBERT, Marcus KOPPITZ